drugset / Trial / NCT03088254

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

NCT03088254

Phase 3 Completed 126 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.

Timeline

Start
2016-09-20
Primary completion
2017-07-31
Completion
2017-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Telmisartan Other / unclassified 80 mg

Indications

No indication recorded.